{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.8","upperLimit":"3.2","value":"3.0"},{"groupId":"OG001","lowerLimit":"4.0","upperLimit":"8.3","value":"8.3"},{"groupId":"OG002","lowerLimit":"10.6","upperLimit":"10.6","value":"10.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"3"}],"units":"Participants"}],"description":"Time to progression (TTP) is defined as the duration of time from the initiation of study treatment with ruxolitinib to first occurrence of either progressive disease or death.","dispersionType":"Inter-Quartile Range","groups":[{"description":"Cohort 1) 5mg ruxolitinib\n\nCarfilzomib: Irreversible proteasome inhibitor\n\nRuxolitinib: Oral JAK inhibitor\n\nDexamethasone: glucocorticoid","id":"OG000","title":"Phase I 5mg Ruxolitinib"},{"description":"Cohort 2) 10mg ruxolitinib\n\nCarfilzomib: Irreversible proteasome inhibitor\n\nRuxolitinib: Oral JAK inhibitor\n\nDexamethasone: glucocorticoid","id":"OG001","title":"Phase I 10mg Ruxolitinib"},{"description":"Cohort 3) 15mg ruxolitinib\n\nCarfilzomib: Irreversible proteasome inhibitor\n\nRuxolitinib: Oral JAK inhibitor\n\nDexamethasone: glucocorticoid","id":"OG002","title":"Phase I 15mg Ruxolitinib"}],"paramType":"MEAN","populationDescription":"All participants who initiate study treatment.","reportingStatus":"POSTED","timeFrame":"approx. 5 years","title":"Time to Progression","type":"SECONDARY","unitOfMeasure":"months"}